Clinical studies of norfloxacin in urinary tract infections by 松浦, 健 & 栗田, 孝
Title尿路感染症に対するNorfloxacinの臨床的検討
Author(s)松浦, 健; 栗田, 孝














CLINICAL STUDIES OF NORFLOXACIN IN URINARY 
            TRACT INFECTION
      Takeshi MATSUURA and Takashi  KURITA 
From the Department of Urology,  Kinki University School of Medicine 
                (Director: Prof. T. Kurita)
   The clinical effectiveness and safety of  norfloxacin were evaluated in 34 patients with 
urinary tract infections. Out of 13 patients with simple  UTI] evaluated by the UTI criteria, 
the results were excellent in 12 cases (92.3%) and moderate in 1 case (7.7%). For complicated 
UTI evaluated by the UTI criteria, the results were excellent in 7 cases (70%), moderate in 2 
cases (20%) and poor in  1 case (10%). The clinical efficacy was satisfactory in the cases of 
2 complicated urinary tract infections as well as simple urinary tract infection. 
   Out of 26 strains of bacteria isolated before treatment, 25 strains(96.2%) were eradica-
ted after treatment. 
   There were no remarkable adverse effects. Only one patient showed slight elevation of 
serum transaminase transiently. 
   From the aboveresults,  norfloxacin is considered to be useful and safe in the treatment 
of urinary tract infection. 


















































































































































































































































Total 15 15(100%) 0
K.Pneumoniae2株を 含 む11株が 分離 され た が,投 与
後10株(90.9%)が消 失 し,存 続 菌 はS.marcescens
1株 のみ で あ った.ま た,投 与 後 出 現菌 と してP.
mirabilis1株が 認 め られ た.
3.副 作 用
薬 剤 投 与 後 の副 作 用 は,臨 床症 状 とし て特 記 す べ き
もの は認 め られ なか った,臨 床検 査 値 も大 きな異 常 を
示 した もの は なか った が,検 討 した21例中,複 雑 性 尿
路 感 染 症 症 例1例 に800mg5日 間 投 薬 後,一 過 性
軽 度 のtransaminase値上 昇(GOT:14→48,


































































































































































































































































































複雑性尿路感染症に対 して も高 い有効率を示 したの
は,む しろ予想しなかったことである.尿路感染症の












けるMICは 低 く,有 効性が 期待できるものと考え
られる.
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